<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="368098">
  <stage>Registered</stage>
  <submitdate>3/03/2015</submitdate>
  <approvaldate>13/03/2015</approvaldate>
  <actrnumber>ACTRN12615000233527</actrnumber>
  <trial_identification>
    <studytitle>An investigative study on the safety and efficacy of French Maritime Pine Bark Extract, Papain and Aloe Vera in pre-diabetic participants</studytitle>
    <scientifictitle>A Phase IIa Double-Blind Placebo Controlled Clinical Trial Investigating the Efficacy and Safety of Arborvitae Health and Wellbeing Supplement on the Blood Glucose Levels in Pre-Diabetic Participants.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Pre-diabetes</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>50 mL of active components or placebo is given by oral solution twice daily. Compliance will be checked by the count of bottles returned and participant's diary. Participants over the age of 18 who demonstrate IFG 6.1-6.9 mmol/L will be recruited for this study. Participants will attend a total of 5 visits. The total duration of the whole study is 12 weeks. 

Active components composition:
Aloe vera 1.75 mg/mL
Papain 2.4 mg/mL
Pinus pinaster 2.6 mg/mL
Sodium chloride 3 mg/mL</interventions>
    <comparator>Two treatment arms, participants will be randomised onto an active or a placebo solution given orally. 

Placebo components composition:
Sodium Chloride 3.0 mg/mL</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Other</interventioncode>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Impared Fasting Glucose.</outcome>
      <timepoint>Bloods are taken for IFG at Screening, Week 4, Week 8, Week 12. </timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Impaired glucose tolerance</outcome>
      <timepoint>Blood samples are taken at Baseline and Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>hs-CRP</outcome>
      <timepoint>Blood samples are taken at Baseline and Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>HbA1c level</outcome>
      <timepoint>Blood samples are taken at Baseline and Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety bloods (ELFTs, Urea, FBC)</outcome>
      <timepoint>Blood samples are taken at Baseline and Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Lipid profile (HDL, LDL, TGs)</outcome>
      <timepoint>Blood samples are taken at Baseline and Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of Life (SF-12v2 Questionnaire)</outcome>
      <timepoint>Questionnaires are filled in at Baseline, Week 4, Week 8 and Week 12</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Men and women who demonstrate IFG from 6.1-6.9 mmol/L</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Major illnesses that are deemed clinically significant; type II diabetes, anyone on anti-obesity medications, dietary supplements. Alcohol abuse. Commencing lifestyle interventions (dietary changes and increasing exercise duration/intensity). </exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Concealment by central randomisation</concealment>
    <sequence>Randomisation blocks</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>False</masking3>
    <masking4>False</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>16/03/2015</anticipatedstartdate>
    <actualstartdate>26/03/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>116</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Arborvitae Health and Wellbeing Pty Ltd</primarysponsorname>
    <primarysponsoraddress>10 Gordon St, Bankstown NSW 2200</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Arborvitae Health and Wellbeing Pty Ltd</fundingname>
      <fundingaddress>10 Gordon St, Bankstown NSW 2200</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The objective of study is to evaluate the safety and efficacy of the investigational product (Pinus Pinaster, Papain, Aloe vera)  in pre-diabetic participants following oral adminstration of 50 mL twice daily. </summary>
    <trialwebsite>http://trialfacts.com/current-trials/</trialwebsite>
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>National Institute Of Integrative Medicine Human Research Ethics Committee</ethicname>
      <ethicaddress>11-23 Burwood Rd, Hawthorn
Melbourne VIC 3122</ethicaddress>
      <ethicapprovaldate>16/02/2015</ethicapprovaldate>
      <hrec>00252</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Luis Vitetta</name>
      <address>Medlab Pty Ltd 66 McCauley st,
Alexandria NSW 2015</address>
      <phone>+61 (02) 8094 1939</phone>
      <fax>+61 (02) 9699 3347</fax>
      <email>luis_vitetta@medlab.co</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Samantha Coulson</name>
      <address>Medlab Pty Ltd 66 McCauley St,
Alexandria NSW 2015</address>
      <phone>+61 (02) 8188 0311</phone>
      <fax />
      <email>samantha_coulson@medlab.co</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Samantha Coulson</name>
      <address>Medlab Pty Ltd 66 McCauley St,
Alexandria NSW 2015</address>
      <phone>+61 (02) 8188 0311</phone>
      <fax />
      <email>samantha_coulson@medlab.co</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Mr</title>
      <name>Tony Nguyen</name>
      <address>Medlab Pty Ltd 66 McCauley St,
Alexandria NSW 2015</address>
      <phone>+61 (02) 8188 0311</phone>
      <fax />
      <email>tony_nguyen@medlab.co</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>